Lihui Wei1,2,3, Julia Petryk4,5, Chantal Gaudet4, Maryam Kamkar4, Wei Gan4,5, Yin Duan4,5, Terrence D Ruddy4,5. 1. Nordion Inc., 447 March Road, Ottawa, ON, K2K 1X8, Canada. lihuiwei@yahoo.com. 2. Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada. lihuiwei@yahoo.com. 3. Nordion Lab, Canadian Molecular Imaging Center of Excellence (C-MICE), University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada. lihuiwei@yahoo.com. 4. Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada. 5. Nordion Lab, Canadian Molecular Imaging Center of Excellence (C-MICE), University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada.
Abstract
BACKGROUND: Chemokine receptor 5 (CCR5) plays an important role in atherosclerosis. Our objective was to develop a SPECT tracer targeting CCR5 for imaging plaque inflammation by radiolabeling D-Ala-peptide T-amide (DAPTA), a CCR5 antagonist, with 111In. METHODS: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) conjugated DAPTA (DOTA-DAPTA) was labeled with 111In. Cell uptake studies were conducted in U87-CD4-CCR5 and U87-MG cells. Biodistribution was determined in C57BL/6 mice. Autoradiography, en face and Oil Red O (ORO) imaging studies were performed in ApoE-/- mice. RESULTS: DOTA-DAPTA was radiolabeled with 111In with high radiochemical purity (> 98%) and specific activity (70 MBq·nmol). 111In-DOTA-DAPTA exhibited fast blood and renal clearance and high spleen uptake. The U87-CD4-CCR5 cells had significantly higher uptake in comparison to the U87-MG cells. The cell uptake was reduced by three times with DAPTA, indicating the receptor specificity of the uptake. Autoradiographic images showed significantly higher lesion uptake of 111In-DOTA-DAPTA in ApoE-/- mice than that in C57BL/6 mice. The tracer uptake in 4 month old ApoE-/- high fat diet (HFD) mice with blocking agent was twofold lower than the same mice without the blocking agent, demonstrating the specificity of the tracer for the CCR5 receptor. CONCLUSION: 111In-DOTA-DAPTA, specifically targeting chemokine receptor CCR5, is a potential SPECT agent for imaging inflammation in atherosclerosis.
BACKGROUND:Chemokine receptor 5 (CCR5) plays an important role in atherosclerosis. Our objective was to develop a SPECT tracer targeting CCR5 for imaging plaque inflammation by radiolabeling D-Ala-peptide T-amide (DAPTA), a CCR5 antagonist, with 111In. METHODS:1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) conjugated DAPTA (DOTA-DAPTA) was labeled with 111In. Cell uptake studies were conducted in U87-CD4-CCR5 and U87-MG cells. Biodistribution was determined in C57BL/6 mice. Autoradiography, en face and Oil Red O (ORO) imaging studies were performed in ApoE-/- mice. RESULTS:DOTA-DAPTA was radiolabeled with 111In with high radiochemical purity (> 98%) and specific activity (70 MBq·nmol). 111In-DOTA-DAPTA exhibited fast blood and renal clearance and high spleen uptake. The U87-CD4-CCR5 cells had significantly higher uptake in comparison to the U87-MG cells. The cell uptake was reduced by three times with DAPTA, indicating the receptor specificity of the uptake. Autoradiographic images showed significantly higher lesion uptake of 111In-DOTA-DAPTA in ApoE-/- mice than that in C57BL/6 mice. The tracer uptake in 4 month old ApoE-/- high fat diet (HFD) mice with blocking agent was twofold lower than the same mice without the blocking agent, demonstrating the specificity of the tracer for the CCR5 receptor. CONCLUSION:111In-DOTA-DAPTA, specifically targeting chemokine receptor CCR5, is a potential SPECT agent for imaging inflammation in atherosclerosis.
Authors: Yan Zhao; Yuji Kuge; Songji Zhao; Koichi Morita; Masayuki Inubushi; H William Strauss; Francis G Blankenberg; Nagara Tamaki Journal: Eur J Nucl Med Mol Imaging Date: 2007-04-17 Impact factor: 9.236
Authors: Marlon P Quinones; Hernan G Martinez; Fabio Jimenez; Carlos A Estrada; Molly Dudley; Opal Willmon; Hemant Kulkarni; Robert L Reddick; Gabriel Fernandes; William A Kuziel; Sunil K Ahuja; Seema S Ahuja Journal: Atherosclerosis Date: 2007-04-26 Impact factor: 5.162
Authors: Michael R Ruff; Maria Polianova; Quan-en Yang; Gifford S Leoung; Francis W Ruscetti; Candace B Pert Journal: Curr HIV Res Date: 2003-01 Impact factor: 1.581
Authors: J H F Rudd; E A Warburton; T D Fryer; H A Jones; J C Clark; N Antoun; P Johnström; A P Davenport; P J Kirkpatrick; B N Arch; J D Pickard; P L Weissberg Journal: Circulation Date: 2002-06-11 Impact factor: 29.690